Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133619) titled 'Value of whole-blood thrombotic molecular biomarkers in assessing the prognosis of patients with sepsis treated with Xuebijing' on Sept. 29.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Guangdong Provincial Hospital of Chinese Medicine
Condition:
Sepsis
Intervention:
Control group:Standard treatment according to the 2021 international guidelines for management of sepsis and septic shock, including early antimicrobial therapy, fluid resuscitation, vasopressors, organ support, and other clinically indicated treatments.
Recruitment Status: Not Recruiting
Phase: 4
Date of First ...